PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
8935.00 - 9125.00
6347.00 - 10045.00
380.0K / 335.9K (Avg.)
23.15 | 391.09
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-37.87%
Cash & equivalents declining -37.87% while Medical - Pharmaceuticals shows -1.85% growth. Howard Marks would investigate if this cash drain is temporary or signals deeper issues.
No Data
No Data available this quarter, please select a different quarter.
-37.87%
Cash + STI yoy growth ≥ 1.5x the Medical - Pharmaceuticals median of -4.30%. Joel Greenblatt would see a liquidity advantage if effectively redeployed.
9.04%
Receivables growth above 1.5x Medical - Pharmaceuticals median of 0.93%. Jim Chanos might see a serious red flag in ballooning receivables.
-3.29%
Inventory growth above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for potential obsolescence or poor planning.
-10.51%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might suspect questionable capitalization or one-time items inflating current assets.
-11.92%
Current assets growth ≥ 1.5x the Medical - Pharmaceuticals median of -2.19%. Joel Greenblatt sees a potential liquidity edge if well allocated.
-2.06%
PP&E growth near the Medical - Pharmaceuticals median of -1.90%. Charlie Munger notes typical capital spending in line with peers.
No Data
No Data available this quarter, please select a different quarter.
-6.07%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos warns of potential intangible bubble or over-capitalized R&D.
-6.07%
Exceeding 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see big intangible expansions as a red flag for future impairments.
-1.48%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects the firm is missing out on growth or is financially constrained.
100.05%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees large expansions in deferred tax assets, possibly pointing to bigger NOLs.
124.48%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a red flag for intangible or questionable expansions in the balance sheet.
3.23%
Below half the Medical - Pharmaceuticals median of -0.74%. Jim Chanos sees a sharp divergence from peers, possibly a sign of strategic retreat or capital shortage.
-100.00%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees potential red flags in big "other" asset lumps.
-1.36%
1.25-1.5x Medical - Pharmaceuticals median of -1.09%. Mohnish Pabrai might see above-average growth. Check if financed sensibly.
-4.05%
Payables growth below half of Medical - Pharmaceuticals median of 1.58%. Joel Greenblatt sees more conservative payables management vs. peers.
No Data
No Data available this quarter, please select a different quarter.
-30.91%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a surge in tax payables that could stress cash flow.
-33.15%
Below half Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potential sales pipeline shortfall.
0.95%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos suspects a potential short-term burden spike.
-4.41%
Below half Medical - Pharmaceuticals median of 1.65%. Joel Greenblatt sees more conservative short-term leverage than peers.
-7.93%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos might see a red flag for ballooning debt load.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.45%
Above 1.5x Medical - Pharmaceuticals median of 0.00%. Jim Chanos sees a potentially alarming surge in other LT obligations.
-3.33%
Above 1.5x Medical - Pharmaceuticals median of -1.15%. Jim Chanos suspects a red flag in ballooning future obligations.
No Data
No Data available this quarter, please select a different quarter.
-4.32%
Below half Medical - Pharmaceuticals median of 0.11%. Joel Greenblatt sees a much lower liability expansion vs. peers.
No Data
No Data available this quarter, please select a different quarter.
1.60%
Below half Medical - Pharmaceuticals median of -1.79%. Jim Chanos suspects poor profitability or large dividend drains.
-5.26%
AOCI growth below half of Medical - Pharmaceuticals median 0.01%. Joel Greenblatt sees fewer exposures vs. peers.
No Data
No Data available this quarter, please select a different quarter.
1.54%
Below half Medical - Pharmaceuticals median of -1.44%. Jim Chanos suspects slower net worth growth or losses vs. peers.
-1.36%
1.25-1.5x Medical - Pharmaceuticals median of -1.09%. Mohnish Pabrai notes above-average growth in liabilities + equity.
-1.48%
≥ 1.5x Medical - Pharmaceuticals median of -0.29%. Joel Greenblatt sees bigger push into investments vs. peers.
-6.02%
Above 1.5x Medical - Pharmaceuticals median of -1.61%. Jim Chanos suspects a big rise in leverage. Check coverage carefully.
57.68%
Below half of Medical - Pharmaceuticals median -0.05%. Joel Greenblatt sees stronger deleveraging or cash accumulation vs. peers.